Evidence map›Paper›PMID 26867157›Full record

Trial reportBritish journal of cancer2016

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.

Niall C Tebbutt, Timothy J Price, Danielle A Ferraro, Nicole Wong, Anne-Sophie Veillard, Merryn Hall, Katrin M Sjoquist, Nick Pavlakis, Andrew Strickland, Suresh C Varma and 6 more

Open access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018
    Pooled it
  3. Pooled it
  4. First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Helicobacter pylori and gastric cancer: a lysosomal protease perspective.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Review
  12. Review
  13. Targeting EGFR in Esophagogastric Cancer.Frontiers in oncology · 2020
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Niall C TebbuttAustin Health, PO Box 5555, Heidelberg, VIC 3084, Australia.
Timothy J PriceThe Queen Elizabeth Hospital, 28 Woodville Road, Woodville South, SA 5011, Australia.
Danielle A FerraroNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
Nicole WongNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
Anne-Sophie VeillardNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
Merryn HallNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
Katrin M SjoquistNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
Nick PavlakisRoyal North Shore Hospital, Pacific Highway, St Leonards, Sydney, NSW 2064, Australia.
Andrew StricklandMonash Medical Centre, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia.
Suresh C VarmaTownsville Hospital, 100 Angus Smith Drive, Douglas, Townsville, QLD 4814, Australia.
Prasad CoorayBox Hill Hospital, Nelson Road, Box Hill, VIC 3128, Australia.
Rosemary YoungRoyal Hobart Hospital, 48 Liverpool Street, Hobart, TAS 7000, Australia.
Craig UnderhillBorder Medical Oncology, 63-69 Nordsvan Drive, Albury, Wodonga, NSW 3690, Australia.
Jennifer A ShannonNepean Cancer Care Centre, Derby Street, Kingswood, Penrith, NSW 2747, Australia.
Vinod GanjuFrankston Hospital, PO Box 52, Frankston, Melbourne, VIC 3199, Australia.
Val GebskiNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia.
The University of Sydney · AUBox Hill Hospital · AUNepean Hospital · AUAustin Health · AUQueen Elizabeth Hospital · AURoyal Hobart Hospital · AURoyal North Shore Hospital · AUTownsville Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis randomised phase II study evaluated the efficacy and safety of panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric cancer.

methodsPatients with metastatic or locally recurrent cancer of the oesophagus, oesophagogastric junction or stomach received docetaxel and a fluoropyrimidine with or without panitumumab for 8 cycles or until progression. The primary end point was response rate (RECIST1.1). We planned to enrol 100 patients, with 50% expected response rate for combination therapy.

resultsA total of 77 patients were enrolled. A safety alert from the REAL3 trial prompted a review of data that found no evidence of adverse outcomes associated with panitumumab but questionable efficacy, and new enrolment was ceased. Enrolled patients were treated according to protocol. Response rates were 49% (95% CI 34-64%) in the chemotherapy arm and 58% (95% CI 42-72%) in the combination arm. Common grade 3 and 4 toxicities included infection, anorexia, vomiting, diarrhoea and fatigue. At 23.7 months of median follow-up, median progression-free survival was 6.9 months vs 6.0 months and median overall survival was 11.7 months vs 10.0 months in the chemotherapy arm and the combination arm, respectively.

conclusionsAdding panitumumab to docetaxel-based chemotherapy for advanced oesophagogastric cancer did not improve efficacy and increased toxicities.

Indexed as

AdenocarcinomaAdultAgedAnorexiaAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCarcinoma, Squamous CellCisplatinDiarrheaDisease-Free SurvivalDocetaxelEsophageal NeoplasmsEsophagogastric JunctionFatigueFemaleAntibodies, MonoclonalCapecitabineCisplatinDocetaxelFluorouracilPanitumumabTaxoids

Identifiers

PMID26867157
PMCPMC4782199
OpenAlexW2313086080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.